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Fludioxonil  is a new generation  fungicide widely used  for postharvest  fruit protection. The 
aim  of  this  study  was  to  produce  hitherto  unreported  immunoreagents  for  fludioxonil 
analysis by  immunoassay. Derivatives of  this agrochemical were synthesized with different 
linker  tethering sites. Those  functionalized haptens were activated, and  the purified active 
esters were  efficiently  conjugated  to  different  carrier  proteins  for  immunogen  and  assay 
antigen preparation. Antibodies to fludioxonil were raised in rabbits and their selectivity and 
affinity were characterized,  revealing  the  significance of  the  linker. Those antibodies were 













and  a  synthetic  derivative  of  pyrrolnitrin  –  an  antibiotic  produced  by  a  number  of 
Pseudomonas species – was launched as a last generation fungicide (1, 2). This molecule was 
registered,  in the mid  ‘90s, under the name  fludioxonil  for postharvest treatment of stone 
fruit,  pome  fruit,  pomegranate,  kiwifruit,  and  citrus  (3,  4). Despite  its  reduced  toxicity  to 
humans,  the  proximity  between  application  and  consumption  make  exposure  risks  a 
concern.  Chromatographic  separation  techniques  coupled  to  mass  spectrometry  are 
commonly applied for fludioxonil residue analysis (5, 6). 
  High‐affinity antibody production  for  small chemicals,  such as  fludioxonil, demands 
accurate  hapten  design  in  order  to  mimic  the  electronic  distribution  and  molecular 
conformation of the target analyte (7, 8). Moreover, the main determinant chemical groups 
should  be  properly  displayed  to  the  immune  system  upon  coupling  to  a  carrier  protein 
through  a  spacer  arm  with  the  adequate  length  (9).  However,  the  optimum  hapten 
derivatization  site  is  still difficult  to predict. The aim of  the present  study was  to prepare 
different  functionalized  fludioxonil  derivatives  for  producing  selective  and  high‐affinity 




Hapten  Synthesis.  Functionalized  derivatives  of  fludioxonil  (haptens  FDc  and  FDn) 






the  corresponding  N‐hydroxysuccinimidyl  ester  (NHS‐ester)  using  N,N’‐disuccinimidyl 
carbonate  (DSC)  and  triethylamine  in  dry  acetonitrile  as  previously  described  (10).  The 
activated hapten was  straightforward purified by  column  chromatography, using CHCl3  as 
eluent; affording the nearly pure NHS esters as determined by the 1H NMR spectra (see the 
Supporting Information).  
Conjugate  Preparation  and  Antibody  Production.  Conjugation  was  carried  out 
following  standard  procedures  as  described  in  the  Supporting  Information.  Hapten‐to‐
protein molar ratios (MR) were calculated from absorbance values of the conjugates and the 
protein at 280 nm. Animal manipulation was performed  in  compliance with  the  laws and 
guidelines of the Spanish Ministry of Agriculture, Fisheries, and Food, and approved by the 
Ethics Committee of the Universitat de València. Antibodies were generated  in rabbits and 
purified  from  the  antisera  following  regular  protocols  as  described  in  the  Supporting 
Information. 
Competitive ELISAs. Assays were performed  following common procedures  for  the 
antibody‐coated  direct  and  the  conjugate‐coated  indirect  cELISA  formats,  as  previously 
published  (11).  Mean  absorbance  values  (492  nm) were  plotted  versus  the  logarithm  of 







obtained  (overall  yield  77%)  from  fludioxonil  in  two  steps,  which  involved  N‐alkylation 
reaction  of  the  pyrrole nitrogen  atom with  tert‐butyl  6‐bromohexanoate  (1),  to  form  the 
N‐alkylated fluodioxonil derivative 2, followed by acid hydrolysis of the tert‐butyl ester group 
(Figure 1). 
The synthesis of hapten FDc started with  the  transformation of  the nitrile group of 
fludioxonil into a carboxylic acid group, which was carried out in two steps. First, the nitrile 
group was  reduced  to  yield  aldehyde  3, whose  subsequent  oxidation  provided  carboxylic 
acid  4.  The  carboxylated  hydrocarbon  chain  that  constituted  the  spacer  arm  was 
incorporated  by  coupling  the  carboxyl  group  of  4  with  the  amine  group  of  6,  previous 
derivatization  of  the  carboxyl  group  to  the  corresponding  N‐succinimidyl  ester,  e.g. 
compound  5. With  amide 7  at hand,  the  synthesis of hapten  FDc was  readily  finished by 
base‐catalyzed hydrolysis of the methyl ester group. The complete synthetic route involved 5 
steps and displayed an overall yield of 54% (Figure 2).  
Hapten  Activation  and  Conjugation.  Hapten  succinimidyl  esters  were  readily 
prepared and purified in high yields (92% and 93% for FDc–NHS and FDn–NHS, respectively) 
using  N,N’‐disuccinimidyl  carbonate.  Activated  purified  haptens  were  coupled  to  bovine 
serum albumin  (BSA), ovalbumin  (OVA), and horseradish peroxidase  (HRP). The amount of 
employed activated hapten was adjusted according to the desired final hapten density. Thus, 
high MRs for BSA conjugates (15 and 17 for FDc and FDn, respectively) and low MRs for OVA 





probably  due  to modified molar  extinction  coefficients  of  the  protein  and/or  the  hapten 




BSA–FDn  immunized  animals),  using  homologous  conjugates  (same  hapten  as  the 
immunizing conjugate) and following the direct and the indirect cELISA procedures. Antibody 
affinity  was  assessed  by  checkerboard  competitive  assays,  running  a  standard  curve  of 
fludioxonil  in each microplate  column  (from 10 pM  to 10 µM plus  a blank),  and  assaying 
diverse antibody and antigen concentrations simultaneously as described  in the Supporting 
Information.  The  lowest  IC50  values  with  homologous  conjugates  were  obtained  with 
antibodies  from  FDn‐immunized  rabbits  in  both  cELISA  formats  (Tables  1  and  2).  Thus, 
hapten  FDn behaved better  as  immunogen  than hapten  FDc,  so  it was  a better mimic of 
fludioxonil. Hapten FDn keeps unmodified all moieties of the  target molecule, and only an 
N–H bond  is  substituted by an N–C bond. Comparatively,  in hapten FDc,  the  cyano group 
modification  probably  alters  more  significantly  the  electronic  properties  of  the  pyrrole 
moiety (Figures 1 and 2). Moreover, the linker in hapten FDn is located further to the bulky 
aryl moiety  than  in  hapten  FDc, which  probably  favors  that  the  aromatic  portion  of  this 
hapten may adopt  similar  conformations  to  those adopted by  the  common  framework of 
parent fludioxonil (see Figure S1 of Supplementary Information).  







Competitive  Immunoassays. Checkerboard  assays were  performed with  both  FDc‐ 
and  FDn‐type  antibodies  using  also  the  heterologous  conjugates.  Concerning  the  direct 
cELISAs, antibody FDc#1 bound the heterologous tracer HRP–FDn, and a moderate IC50 value 
to  fludioxonil was  found  in  this case,  improving  the  IC50 value  that was obtained with  the 
homologous  combination. However, FDn‐type antibodies  recognized only  the homologous 
tracer.  Parallel  results were  observed with  the  indirect  format  (Table  2).  For  a  particular 
antibody/antigen  combination,  the  IC50  values  stayed  in  the  same  order  of magnitude  in 
both  cELISA  formats. Overall,  the most  sensitive assay was achieved with antibody FDn#1 


















Supporting  Information  Available:  Synthesis  details  and  characterization  data  of 
intermediates,  haptens,  and  active  esters.  Equipment,  immunoreagent  production,  ELISA 
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Table 1. Assay sensitivity in the direct cELISA format. 
  Tracer conjugate 
  HRP−FDc  HRP−FDn 
Ab  [Ab]a [C]b Amax IC50c  [Ab] [C] Amax IC50 
FDc#1  30 3 1.0 1366.4  3 100 0.8 92.0 
FDc#2  3 10 1.8 1542.6  3 100 --- --- 
FDn#1  3 100 --- ---  10 3 0.8 22.9 
FDn#2  3 100 --- ---  30 10 1.2 129.5 
a Antibody dilution (×103). b Conjugate concentration in ng/mL.  
c Values in nM. 
Table 2. Assay sensitivity in the indirect cELISA format. 
  Coating conjugate 
  OVA−FDc  OVA−FDn 
Ab  [Ab]a [C]b Amax IC50c  [Ab] [C] Amax IC50 
FDc#1  300 100 1.1 1405.7  10 1000 0.9 88.1 
FDc#2  100 100 0.8 1329.4  10 1000 0.8 --- 
FDn#1  3 1000 --- ---  30 100 1.5 75.1 
FDn#2  3 1000 --- ---  100 100 1.0 372.8 
a Antibody dilution (×103). b Conjugate concentration in ng/mL. 
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General experimental details 
The progress of reactions was monitored by thin layer chromatography (TLC) performed 
on F254 silica gel plates. The plates were visualized by immersion with ethanolic ceric 
ammonium molybdate or phosphomolybdic acid or aqueous sulphuric acid and heating. 
Column chromatography refers to flash chromatography and was performed on Merck silica 
gel 60, 230-400 mesh. All operations involving air-sensitive reagents were performed under 
an inert atmosphere of dry argon using syringe and cannula techniques, oven-dried 
glassware, and freshly distilled and dried solvents. Solvents and reagents were purified by 
standard methods.1 
All melting points were determined using a Kofler hot-stage apparatus and are 
uncorrected. IR spectra were measured as KBr pellets or liquid films using a Nicolet Avatar 
320 spectrometer. High-resolution mass spectra (HRMS) were run either by the electron 
impact (EI, 70 eV) obtained with a Micromass VG Autospec spectrometer, or the 
electrospray (ES) mode, which was obtained with a Q-TOF premier mass spectrometer with 
an electrospray source (Waters, Manchester, UK). 1H NMR spectra were recorded on Bruker 
spectrometers, in the solvent indicated, at 300 MHz and 13C NMR spectra at 75 MHz. 19F 
NMR spectra were acquired at 282 MHz with high power proton decoupling. All proton and 
carbon spectra were referenced to residual solvent (1H NMR: 7.26 ppm for CDCl3, 3.58 ppm 
for THF-d8, 3.31 ppm for MeOH-d4, and 2.50 ppm for DMSO-d6); 13C NMR: 77.00 ppm for 
CDCl3, 67.57 ppm for THF-d8, 49.00 ppm for MeOH-d4 and 39.52 ppm for DMSO-d6). 19F 
spectra were referenced to CFCl3 as the internal reference which was set at δ 0.00 ppm. 
Carbon substitution degrees were established by DEPT pulse sequences. Complete 
assignment of 1H and 13C chemical shifts of selected compound in the synthetic sequence 
was made on the basis of a combination of COSY and HSQC experiments. 
 
Synthesis of hapten FDn 
The synthesis of hapten FDn is depicted Figure 1 of the article. 
tert-Butyl 6-(3-cyano-4-(2,2-difluorobenzo[d][1,3]dioxol-4-yl)-1H-pyrrol-1-yl) 
hexanoate (2). A solution of fluodioxonil (93.4 mg, 0.38 mmol) in DMF (0.4 mL) was added 
dropwise to a stirred suspension of prewashed (pentane) NaH (60% dispersion in mineral oil, 
33 mg, 0.82 mmol) in anhydrous DMF (0.3 mL) under nitrogen. After stirring for 2 h at rt, a 
solution of sodium iodide (15.2 mg, 0.10 mmol) and tert-butyl 6-bromohexanoate (1, 142 mg, 
0.56 mmol) in DMF (0.6 mL) was added and the mixture was stirred for an additional 3 h, 
then poured into water and extracted with ether. The combined organic layers were washed 
with a 2% aqueous solution of LiCl and brine and dried over anhydrous MgSO4. The solvent 
                                                            




was removed under vacuum and the residue was chromatographed, using hexane-EtOAc 
mixtures (from 100:0 to 80:20), to give the ester 2 (126 mg, 80%) as an oil. IR (NaCl) 
νmax/cm-1: 3129, 2977, 2222, 1720, 1651, 1552, 1527, 1244, 1152, 763, 721. 1H NMR (300 
MHz, CHCl3) δ (ppm): 7.70 (1H, dd, J = 8.1, 1.1 Hz), 7.25 (1H, d, J = 2.3 Hz), 7.14 (1H, d, J = 
2.3 Hz), 7.12 (1H, dd, J = 8.1, 8.1 Hz), 6.95 (1H, dd, J = 8.1, 1.1 Hz), 3.95 (2H, t, J = 7.5 Hz), 
2.22 (2H, t, J = 7.5 Hz), 1.84 (2H, quint, J = 7.4 Hz), 1.63 (2H, quint, J = 7.2 Hz), 1.42 (9H, s), 
1.35 (2H, m). 13C NMR (75 MHz, CHCl3) δ (ppm): 172.6 (C), 143.7 (C), 139.7 (C), 131.3 (t, J 
= 255 Hz, C), 129.5 (CH), 124.0 (CH), 122.3 (CH), 121.2 (CH), 118.5 (C), 116.5 (C), 116.4 
(C), 107.7 (CH), 91.0 (C), 80.2 (C), 50.4 (CH2), 35.1 (CH2), 30.7 (CH2), 28.0 (CH3), 25.8 
(CH2), 24.3 (CH2). 19F NMR (282 MHz, CHCl3) δ (ppm): −49.96. HRMS (TOF MS ES+) m/z: 
calcd for C22H25F2N2O4 [M+H]+ 419.1782, found 419.1786.  
6-(3-Cyano-4-(2,2-difluorobenzo[d][1,3]dioxol-4-yl)-1H-pyrrol-1-yl)hexanoic acid 
(hapten FDn). tert-Butyl ester 2 (87 mg, 0.21 mmol) was dissolved in cooled (0 ºC) formic 
acid (2 mL) and the solution was stirred at 0–4 ºC for 3 h and then at rt for an additional 30 
min. The reaction mixture was diluted with benzene and concentrated to dryness under 
vacuum (bath temperature not higher than 40 ºC). The residue was dissolved in benzene and 
the mixture concentrated again to dryness, to obtain hapten FDn (72 mg, 96%) as a white 
solid. Mp 100–102 ºC (crystallized from cool benzene–hexane). IR (NaCl) νmax/cm−1: 3500–
2500, 3136, 2943, 2220, 1705, 1549, 1525, 1258, 1133, 762, 718. 1H NMR (300 MHz, 
CHCl3) δ: 11.2 (1H, br s), 7.71 (1H, dd, J = 8.1, 1.0 Hz), 7.24 (1H, d, J = 2.3 Hz), 7.15 (1H, d, 
J = 2.3 Hz), 7.13 (1H, dd, J = 8.1, 8.1 Hz), 6.96 (1H, dd, J = 8.1, 1.0 Hz), 3.97 (2H, t, J = 7.1 
Hz), 2.39 (2H, t, J = 7.0 Hz), 1.87 (2H, quint, J = 7.3 Hz), 1.70 (2H, quint, J = 7.2 Hz), 1.39 
(2H, m). 13C NMR (75 MHz, CHCl3) δ (ppm): 179.4 (C), 143.8 (C), 139.7 (C), 131.3 (t, J = 
255 Hz, C), 129.5 (CH), 124.0 (CH), 122.3 (CH), 121.2 (CH), 118.6 (C), 116.5 (C), 116.4 (C), 
107.7 (CH), 91.0 (C), 50.4 (CH2), 33.6 (CH2), 30.6 (CH2), 25.8 (CH2), 23.9 (CH2). 19F NMR 
(282 MHz, CHCl3) δ (ppm): −49.95. HRMS (TOF-MS–ES+) m/z: calcd for C18H17F2N2O4 
[M+H]+ 363.1156, found 363.1151. 
 
Synthesis of hapten FDc 
The synthesis of hapten FDc is depicted Figure 2 of the article.  
4-(2,2-Difluorobenzo[d][1,3]dioxol-4-yl)-1H-pyrrole-3-carbaldehyde (3). A solution of 
DIBAL-H in toluene (1M, 2.3 mL, 2.3 mmol) was dropwise added to a solution of fludioxonil 
(400 mg, 1.61 mmol) in anhydrous Et2O (20 mL) at −60 ºC under nitrogen. The reaction 
mixture was stirred while it was allowed to warm to −30 ºC during the course of 1 h and kept 
at this temperature for 30 min, then the cooling bath was retired and the reaction mixture 
stirred for 1 h. After this time, the reaction mixture was transferred via cannula to a slurry of 
silica gel (1.8 g) in water (0.7 mL), cooled at 0 ºC, and the mixture stirred at this temperature 
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for 1 h and then at rt for an additional 1 h. Solid K2CO3 (2.68 g) and MgSO4 (2.68 g) were 
added and the stirring was continued for another 1 h, then filtered under vacuum using a 
Büchner funnel and the filtrate and washings were concentrate to dryness to give the 
aldehyde 3 (371 mg, 92%) as a solid, which was used to the next step without further 
purification. Mp 143.7–146.1 ºC (from hexane-EtOAc). IR (KBr) νmax/cm−1: 3281, 3924, 1659, 
1453, 1317, 1233, 1133, 1099, 1050, 762, 716. 1H NMR (300 MHz, CDCl3) δ (ppm): 9.93 
(1H, s), 8.88 (1H, br s), 7.56 (1H, dd, J = 3.2, 2.2 Hz), 7.44 (1H, dd, J = 8.1, 1.2 Hz), 7.17 
(1H, dd, J = 2.2, 2.2 Hz), 7.12 (1H, dd, J = 8.0, 8.0 Hz), 6.99 (1H, dd, J = 8.0, 1.2 Hz). 13C 
NMR (75 MHz, CDCl3) δ (ppm): 185.6 (CH), 143.7 (C), 140.9 (C), 131.4 (t, J = 254 Hz, C), 
128.5 (CH), 125.0 (CH), 123.8 (C), 123.4 (CH), 121.0 (CH), 117.4 (C), 117.2 (C), 107.9 (CH). 
19F NMR (282 MHz, CHCl3) δ (ppm): −50.17. HRMS (TOF MS ES+) m/z: calcd for 
C12H8F2NO3 [M+H]+ 252.0472, found 252.0478. 
4-(2,2-Difluorobenzo[d][1,3]dioxol-4-yl)-1H-pyrrole-3-carboxylic acid (4). A solution of 
NaClO2 (800 mg, 8.84 mmol), and NaH2PO4·H2O (1.129 g, 1.18 mmol) in water (3.2 mL) and 
2-methyl-2-butene (836 mg, 1.26 mL 11.92 mmol) were consecutively added to a solution of 
aldehyde 3 (318.6 mg, 1.27 mmol) in tert-BuOH (2.5 mL) cooled to 0 ºC. The reaction flask 
was tightly closed and the mixture was allowed to warm to rt and stirred overnight. The 
reaction mixture was poured into water and extracted with Et2O. The ethereal layer was 
extracted with a 1 M solution of NaOH and the ethereal layer was washed with brine, dried 
over anhydrous MgSO4 and concentrated to afford unreacted starting aldehyde 3 (29.9 mg, 
9.4%). The aqueous layer was acidified to pH 4–5 with citric acid and extracted with Et2O. 
The combined organic layer were washed with brine, dried over anhydrous MgSO4 and 
concentrated to dryness under vacuum to afford the acid 4 [268.1 mg, 84% (93% based on 
recovered starting material)] as a solid that was pure enough to be used in the next step 
without further purification. Mp 188–189.0 ºC (from hexane-EtOAc). IR (KBr) νmax/cm−1: 
3500–2500, 3126, 2885, 1668, 1535, 1454, 1241, 1156, 780, 578. 1H NMR (300 MHz, 
DMSO-d6) δ (ppm): 11.84 (1H, br s), 11.65 (1H, br s), 7.47 (1H, dd, J = 2.7, 2.4), 7.25–7.14 
(3H, m), 7.02 (1H, t, J = 2.4, 2.4). 13C NMR (75 MHz, DMSO-d6) δ (ppm): 165.1 (C), 142.4 
(C), 140.6 (C), 130.9 (t, J = 251 Hz, C), 125.5 (CH), 125.4 (CH), 123.3 (C), 120.1 (CH), 119.3 
(C), 116.4 (C), 113.8 (C), 107.5 (CH). 19F NMR (282 MHz, DMSO-d6) δ (ppm): −49.26. 
HRMS (TOF MS ES-) m/z: calcd for C12H7F2NO4 [M-H]+ 266.0265, found 266.0269. 
Methyl 6-(4-(2,2-difluorobenzo[d][1,3]dioxol-4-yl)-1H-pyrrole-3-carboxamido) 
hexanoate (7). Anhydrous Et3N (409 L, 297 mg, 2.93 mmol) was added to a solution of 
acid 4 (206.5 mg, 0.773 mmol) and N,N′-disuccinimidyl carbonate (DSC, 257 mg, 1.00 mmol) 
in anhydrous CH3CN (7 mL) at 0 ºC under nitrogen and the mixture was stirred at this 
temperature for 2 h. The solvent and the excess Et3N were eliminated at reduced pressure, 
and the residue was purified by column chromatography, eluting first with CH2Cl2 and then 
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with CHCl3, to give the succinimidyl ester intermediate 5 (250.6 mg, 89%). 1H NMR (300 
MHz, CHCl3) δ (ppm): 9.59 (1H, br s), 7.65 (1H, dd, J = 3.3, 2.1), 7.21 (1H, dd, J = 8.1, 1.5 
Hz), 7.02 (1H, dd, J = 8.1, 8.1 Hz), 7.00 (1H, dd, J = 3.3, 1.5 Hz), 6.94 (1H, dd, J = 8.1, 1.5 
Hz), 2.86 (4H, s). 
A solution of methyl 6-amino-hexanoate hydrochloride (6, 152.6 mg, 0.84 mmol) and Et3N 
(129 L, 93.5 mg, 0.924 mmol) in anhydrous DMF (4 mL) was added to a solution of the 
above obtained succinimidyl ester 5 (102 mg, 0.280 mol) in DMF (0.5 mL). The mixture was 
stirred at rt for 4 h, diluted with water and extracted with Et2O. The combined organic extracts 
were washed with a 2% aqueous solution of LiCl and brine and dried over anhydrous 
MgSO4. Chromatographic purification of the residue left after evaporation of the solvent, 
using CHCl3 as eluent, afforded the amide 7 (99.5 mg, 90%) as an oil. IR (KBr) νmax/cm−1: 
3335, 3131, 2947, 1736, 1653, 1603, 1561, 1458, 1239, 1144, 1110, 771. 1H NMR (300 
MHz, CDCl3) δ (ppm): 9.92 (1H, br s), 7.32 (1H, dd, J = 2.3, 2.3 Hz), 7.15 (1H, dd, J = 7.9, 
1.3 Hz), 7.06 (1H, dd, J = 7.9, 7.9 Hz), 6.96 (1H, dd, J = 7.9, 1.3 Hz), 6.90 (1H, dd, J = 2.3, 
2.3 Hz), 5.66 (1H, br t, J = 5.5 Hz), 3.64 (3H, s), 3.30 (2H, q, J = 6.9 Hz), 2.26 (2H, t, J = 7.4 
Hz), 1.59 (2H, t, quint, J = 7.4 Hz), 1.45 (2H, m), 1.24 (2H, m). 13C NMR (75 MHz, CDCl3) δ 
(ppm): 174.1 (C), 165.7 (C), 143.7(C), 141.0 (C), 131.3 (t, J = 252 Hz, C), 124.7 (CH), 
123.5(CH), 122.4 (C), 119.7 (CH), 118.3 (C), 118.2 (C), 114.6 (C), 107.7 (CH), 51.5 (OCH3), 
39.3 (CH2), 33.8 (CH2), 29.1 (CH2), 26.3 (CH2), 24.5 (CH2). 19F NMR (282 MHz, CHCl3) δ 
(ppm): −50.07. HRMS (TOF MS ES-) m/z: calcd for C19H20F2N2O5 [M-H] + 393.1262, found 
393.1258. 
6-(4-(2,2-Difluorobenzo[d][1,3]dioxol-4-yl)-1H-pyrrole-3-carboxamido)hexanoic acid 
(hapten FDc). A solution of the methyl ester 7 (112.5 mg, 0.285 mmol) in a mixture of THF 
(2.3 mL) and H2O (0.95 mL) was treated with LiOH·H2O (120.4 mg, 2.869 mmol) and stirred 
at rt for 2.5 h. The reaction mixture was diluted with H2O (20 mL) and extracted with ethyl 
ether. The organic layer was discarded and the aqueous layer was evaporated under 
vacuum to eliminate the remains of organic solvent, then cooled in an ice bath and acidified 
with a saturated aqueous solution of KHSO4 to approximately pH 3. The precipitate formed 
was filtered off, washed with water and dried to afford the hapten FDc (96 mg, 88%) as a 
semi-solid. IR (KBr) νmax/cm−1: 3500–2500, 2936, 1712, 1654, 1605, 1544, 1453, 1235, 1149, 
723. 1H NMR (300 MHz, THF-d8) δ (ppm): 10.7 (1H, br s), 7.42 (1H, dd, J = 8.1, 1.5 Hz), 7.17 
(1H, dd, J = 2.7, 2.4 Hz), 7.04 (1H, dd, J = 7.8, 7.8 Hz), 6.98–6.94 (2H, a dd overlapped with 
other dd of J = 8.1, 1.2 Hz), 6.83 (1H, br t, J = 5.7 Hz), 3.25 (2H, q, J = 6.5 Hz), 2.21 (2H, t, J 
= 7.5 Hz), 1.53 (4H, m), 1.35 (2H, m). 13C NMR (75 MHz, THF-d8) δ (ppm): 174.7 (C), 165.9 
(C), 144.4 (C), 141.6 (C), 132.5 (t, J = 253 Hz, C), 126.3(CH), 124.0 (CH), 122.1 (CH), 120.8 
(C), 120.6 (CH), 120.4 (C), 116.2 (C), 107.3 (CH), 40.0 (CH2), 34.3 (CH2), 30.6 (CH2), 27.7 
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(CH2), 25.8 (CH2). 19F NMR (282 MHz, THF-d8) δ (ppm): −45.78. HRMS (TOF MS ES+) m/z: 
calcd for C18H19F2N2O5 [M+H]+ 381.1262, found 381.1260. 
 
1H NMR spectra of NHS-esters of haptens FDc and FDn 
FDc–NHS ester (1 h at 0 °C; 92% yield): 1H-NMR (300 MHz, CDCl3)  (ppm) 9.42 (1H, br 
s), 7.30 (1H, dd, J = 2.8, 2.3 Hz), 7.17 (1H, dd, J = 7.9, 1.3 Hz), 7.09 (1H, dd, J = 7.9, 7.9 
Hz), 6.97 (1H, dd, J = 7.9, 1.3 Hz), 6.94 (1H, dd, J = 2.3, 2.3 Hz), 5.74 (1H, t, J = 5.7 Hz), 
3.31 (2H, q, J = 6.5 Hz), 2.81 (4H, br s), 2.56 (2H, t, J = 7.3 Hz), 1.72 (2H, t, quint, J = 7.1 
Hz), 1.49 (2H, quint, J = 7.1 Hz), 1.35 (2H, m). 
FDn–NHS ester (4 h at room temperature; 93% yield): 1H-NMR (300 MHz, CDCl3)  (ppm) 
7.71 (1H, dd, J = 8.2, 1.1 Hz), 7.26 (1H, d, J = 2.0 Hz), 7.16 (1H, d, J = 2.0 Hz), 7.12 (1H, dd, 
J = 8.1, 8.1 Hz), 6.96 (1H, dd, J = 8.1, 1.1 Hz), 3.97 (2H, t, J = 7.1 Hz), 2.84 (4H, br s), 2.63 
(2H, t, J = 7.1 Hz), 1.85 (4H, m), 1.47 (2H, m). 
 
Chemicals and instrumentation 
Pestanal grade fludioxonil (4-[2,2-difluoro-1,3-benzodioxol-4-yl]-1H-pyrrole-3-carbonitrile, 
CAS registry number 131341-86-1, Mw 249.19) was purchased from Fluka/Riedel-de-Haën 
(Seelze, Germany). Other chemicals were obtained from standard sources. Bovine serum 
albumin (BSA) fraction V was from Roche Applied Science (Mannheim, Germany). 
Ovalbumin (OVA) and horseradish peroxidase (HRP) were purchased from Sigma/Aldrich 
(Madrid, Spain). 
Sephadex G-25 HiTrap Desalting columns from GE Healthcare (Uppsala, Sweden) were 
utilized for protein–hapten conjugate purification. Costar flat-bottom high-binding 96-well 
polystyrene ELISA plates were from Corning (Corning, NY, USA). UV–visible spectra and 
ELISA absorbances were read with a PowerWave HT from BioTek Instruments (Winooski, 
VT, USA). Microwells were washed with an ELx405 microplate washer also from BioTek 
Instruments. 
 
Hapten activation  
The hapten (1 equiv) and DSC (1.3 equiv) were dissolved in anhydrous acetonitrile (1 mL 
per 0.1 mmol of hapten) under nitrogen in an ice-water bath. Triethylamine (3.5 equiv) was 
then added, and the resulting mixture was stirred at 0 °C or at room temperature for haptens 
FDc and FDn, respectively, until complete consumption of the starting material (as observed 
by thin layer chromatography using CHCl3:MeOH 9:1 as eluent). The reaction mixture was 
diluted with CHCl3, washed with a 10% aqueous solution of NaHCO3 and brine, and dried 
over anhydrous Na2SO4. After evaporation of the solvent,  the activated hapten was purified 





Conjugation was carried out in carbonate buffer, pH 9.6, during 2 h under moderate stirring 
at room temperature. Immunizing conjugates were prepared by reaction of 10 µmol of 
purified activated hapten in DMF (100 µL) with 30 mg of BSA in carbonate buffer (2 mL). For 
coating conjugates, 2 µmol of activated hapten in DMF (100 µL) was conjugated to 30 mg of 
OVA in the described buffer (2 mL), whereas for enzyme assay conjugates, 0.5 µmol of 
active ester solution in DMF (50 µL) was reacted with 2.2 mg of HRP in carbonate buffer 
(1 mL). Conjugates were purified by gel filtration chromatography using 100 mM phosphate 
buffer, pH 7.4 as eluent. BSA and OVA conjugates were stored frozen at −20 °C, and HRP 
conjugates were kept at 4 °C. 
 
Antibody production 
With each immunogen, two antisera were generated from two 2-kg female New Zealand 
white rabbits, which had been immunized, with 21-day intervals, by subcutaneous injection of 
0.3 mg of BSA–hapten conjugate in 1 mL of a 1:1 emulsion between 100 mM phosphate, pH 
7.4, and Freund’s adjuvant (complete for the first dose and incomplete for subsequent 
boosts). Ten days after the fourth injection, rabbits were exsanguinated. Blood samples were 
allowed to coagulate overnight at 4 °C, and sera were separated by centrifugation. Finally, 
antibodies were precipitated with 1 volume of saturated ammonium sulfate solution. Salting 
out was performed twice, and precipitates were stored at 4 °C. 
 
Checkerboard competitive assays 
For the direct format, three different antibody dilutions (1/3000, 1/10000, and 1/30000) and 
four enzyme tracer concentrations (3, 10, 30, and 100 ng/mL) were assayed in the same 
plate. For indirect competitive assays, plates were coated with 100 or 1000 ng/mL OVA 
conjugate, and diverse antibody dilutions were assayed from 1/3000 to 1/300000 in one 
plate. Consequently, 12 inhibition curves were retrieved from every plate; each curve 
corresponding to a particular antibody and assay conjugate concentration. Absorbance was 
read immediately after assays at 492 nm with a reference wavelength at 650 nm. 
Experimental values were fitted to a four-parameter logistic equation using the SigmaPlot 






Graph of potential energy of fludioxonil as a function of the dihedral angle between the 
benzene and pyrrole rings and its most stable conformations (arrows denote the attachment 






















Inhibition curve obtained with antibody FDn#1 and tracer HRP–FDn in the direct cELISA 
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